China Factory Activity Extends Growth in April Despite Global Pressures 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Inflation Surges in March as Fuel Prices Spike Amid Middle East Conflict 
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade 
Tokyo Inflation Slows Despite Energy Pressures and BOJ Policy Outlook 
US Dollar Weakens as Yen Surges Amid Japan Intervention and Central Bank Moves 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Kevin Warsh Advances Toward Fed Chair Role Amid Political Tensions 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears 
US Stock Futures Rise as S&P 500 and Nasdaq Hit Record Highs Amid Earnings Optimism and Iran Tensions 
Asian Stock Markets Rise Amid Wall Street Rally and U.S.-Iran Tensions 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
KT Corp. has collaborated with US-based NeuroSigma Inc. to build a business model and technology for electronic medicine to treat neurological disorders, such as attention deficit hyperactivity disorder (ADHD), depression, and epilepsy.
Under the partnership, KTS will support the development of the next version of NeuroSigma's external trigeminal nerve stimulation (eTNS®) system while producing and commercializing the device in South Korea.
NeuoSigma is credited for developing the first device cleared by the US Food and Drug Administration to treat pediatric ADHD--the Monarch external Trigeminal Nerve Stimulation system,
The telecom operator said NeuoSigma's pediatric ADHD electronic treatment has fewer side effects than other existing medication and is set to receive further clearance from the FDA on depression and epilepsy treatment using the technology.
